Historique
Périodique
Naltrexone shortened opioid detoxification with buprenorphine
(Diminution du temps de sevrage d'opiacés sous naltrexone par la buprénorphine)
Auteur(s) :
A. UMBRICHT ;
I. D. MONTOYA ;
D. R. HOOVER ;
DEMUTH K. L. ;
C. T. CHIANG ;
K. L. PRESTON
Article en page(s) :
181-190
Refs biblio. :
32
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Thésaurus mots-clés
BUPRENORPHINE
;
NALTREXONE
;
OPIACES
;
SEVRAGE
;
SYNDROME DE SEVRAGE
;
EFFICACITE
Note générale :
Drug and Alcohol Dependence, 1999, 56, (3), 181-190
Note de contenu :
graph.
Résumé :
FRANÇAIS :
La naltrexone couramment utilisée pour le sevrage d'opiacés diminue la durée du syndrome de sevrage, mais en augmente l'intensité. La buprénorphine est parfois utilisée pour réduire les effets de sevrage en association avec la naltrexone. Cette étude compare l'action de la buprénorphine administrée pendant 4 jours avec la naltrexone et l'action de la buprénorphine administrée seule. Il semble que l'association des deux médicaments soit une méthode acceptable pour réduire les effets de sevrage.
ENGLISH :
This double-blind, randomized, placebo-controlled clinical trial evaluated the impact on withdrawal symptoms of (i) combining naltrexone with a 4-day buprenorphine taper for short opioid detoxification (NB Group), compared to (ii) using a 4-day buprenorphine taper alone, followed by naltrexone on day 8 (PB Group). Sublingual buprenorphine was administered on days 1-4 (26 mg total). For the NB Group (n = 32) escalating doses of oral naltrexone were given on days 2-8 (placebo day 1). For the PB Group (n = 28) placebo was given on days 1-7 and naltrexone on day 8. Main outcome measures were Observed Opioid Withdrawal scores (OOW, 0-30) and use of medications to treat opioid withdrawal. Of 32 patients in the NB group, 59% experienced clinically relevant withdrawal (defined as OOW > 5) on day 2, but, after day 5, none experienced withdrawal. In the PB group, the number of patients experiencing withdrawal increased over time. The first naltrexone dose induced comparable withdrawal in both groups: peak OOW scores were (mean + SD) 5.2 + 3.3 on day 2 for the NB group, and 4.0 + 3.9 on day 8 for the PB group (NS), though, on day 2,7 patients dropped out in the NB group and none in the PB group, while only one patient dropped out in the PB group on day 8. Throughout the 8-day study, patients in both groups received similar amount of adjunct medication: 0.64 + 0.07 mg (NB group) of clonidine vs 0.73 + 0.15 mg (PB group; NS). Only 25% of patients required use of sedatives (up to 20 mg diazepam). Starting naltrexone on day 2 appeared to abolish withdrawal symptoms after day 5 and, thus, to shorten the duration of withdrawal symptoms. Peak withdrawal symptoms after naltrexone combined with buprenorphine is an acceptable and safe treatment for shortened opioid detoxification and induction of naltrexone maintenance. (Author' s abstract)
La naltrexone couramment utilisée pour le sevrage d'opiacés diminue la durée du syndrome de sevrage, mais en augmente l'intensité. La buprénorphine est parfois utilisée pour réduire les effets de sevrage en association avec la naltrexone. Cette étude compare l'action de la buprénorphine administrée pendant 4 jours avec la naltrexone et l'action de la buprénorphine administrée seule. Il semble que l'association des deux médicaments soit une méthode acceptable pour réduire les effets de sevrage.
ENGLISH :
This double-blind, randomized, placebo-controlled clinical trial evaluated the impact on withdrawal symptoms of (i) combining naltrexone with a 4-day buprenorphine taper for short opioid detoxification (NB Group), compared to (ii) using a 4-day buprenorphine taper alone, followed by naltrexone on day 8 (PB Group). Sublingual buprenorphine was administered on days 1-4 (26 mg total). For the NB Group (n = 32) escalating doses of oral naltrexone were given on days 2-8 (placebo day 1). For the PB Group (n = 28) placebo was given on days 1-7 and naltrexone on day 8. Main outcome measures were Observed Opioid Withdrawal scores (OOW, 0-30) and use of medications to treat opioid withdrawal. Of 32 patients in the NB group, 59% experienced clinically relevant withdrawal (defined as OOW > 5) on day 2, but, after day 5, none experienced withdrawal. In the PB group, the number of patients experiencing withdrawal increased over time. The first naltrexone dose induced comparable withdrawal in both groups: peak OOW scores were (mean + SD) 5.2 + 3.3 on day 2 for the NB group, and 4.0 + 3.9 on day 8 for the PB group (NS), though, on day 2,7 patients dropped out in the NB group and none in the PB group, while only one patient dropped out in the PB group on day 8. Throughout the 8-day study, patients in both groups received similar amount of adjunct medication: 0.64 + 0.07 mg (NB group) of clonidine vs 0.73 + 0.15 mg (PB group; NS). Only 25% of patients required use of sedatives (up to 20 mg diazepam). Starting naltrexone on day 2 appeared to abolish withdrawal symptoms after day 5 and, thus, to shorten the duration of withdrawal symptoms. Peak withdrawal symptoms after naltrexone combined with buprenorphine is an acceptable and safe treatment for shortened opioid detoxification and induction of naltrexone maintenance. (Author' s abstract)
Affiliation :
NIDA Intramur. Res. Prog., Addict. Res. Ctr, 5500 Nathan Shock Drive, POB 5180, Baltimore, MD 212224
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |